EverFlex™ Stent System with Entrust™ Delivery System

The United States Study for Evaluating Endovascular Treatments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By using the Protégé EverFlex Nitinol Stent System II (DURABILITY II).

Matsumura JS, et al. J Vasc Surg. 2013;58:73–83.e1.

A Single Stent Strategy in Patients with Lifestyle Limiting Claudication: 3-Year Results from the DURABILITY II Trial.

Rocha-Singh KJ, et al. Catheter Cardiovasc Interv. 2015;86:164–170.

The Impact of Sex on Angioplasty and Primary Stenting for Femoropopliteal Occlusive Disease: Results of the DURABILITY II Trial.

Tedros RO, et al. Ann Vasc Surg. 2014;28:1–9.

Intermediate Outcomes of Femoropopliteal Stenting in Women: 3-Year Results of the DURABILITY II Trial.

Han DK, et al. Ann Vasc Surg. 2016;30:110–117.

Results of the Protégé EverFlex 200-mm-long Nitinol Stent (ev3) in TASC C and D Femoropopliteal Lesions.

Bosiers M, et al. J Vasc Surg. 2011;54:1042–1050.